We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
Philip
Quirke
P.Quirke@leeds.ac.uk
Prof
Philip
Quirke
P.Quirke@leeds.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Bowel cancer is the second most deadly cancer in the UK, killing on average 16,000 people each year. Cancer occurs as a result of changes, or ‘mutations’, in the DNA within cells. Currently, if a patient undergoes a biopsy or if the whole tumour is surgically removed (resection), this tissue can be tested for the presence of mutations.
Tumours release tiny amounts of DNA and cells into the blood and stool, which can also be tested for the presence of mutations. Being able to detect these mutations will improve our ability to screen for the presence of cancer, provide information about a patient’s diagnosis and determine which treatment options are best for each patient.
We have the opportunity to collaborate with two industrial partners to improve both the isolation of cancer cells from blood and stool samples and also the screening of these cells for the presence of mutations.
Mikro Biyo have developed a novel technology which separates out circulating tumour cells (CTCs) and potentially circulating tumour DNA (ctDNA) from patient blood samples. The benefits of this technique are the sensitivity and also the speed with which the blood can be processed.
Genefirst have developed “ATOM-seq”, a super-sensitive technology, allowing the processing and sequencing of tiny amounts of the tumour DNA from patient blood and stool samples, to identify mutations. This novel technology could be implemented downstream of the CTC and ctDNA isolation, thus complementing the Mikro Biyo technology.
We wish to obtain surplus tumour tissue, blood samples and stool samples from patients with bowel cancer, to compare the mutation profile of each sample type. We also wish to obtain stool samples from patients who have undergone a colonoscopy, to determine whether “ATOM-seq” could be used to further identify patients ‘at risk’ of cancer development.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
- Aged less than 18 or over 115. - Unable to give informed consent. - Patients with a diagnosis of a non-colorectal adenocarcinoma.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University of Leeds and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 46173
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
